WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG CHRONIC SPONTANEOUS/IDIOPATHIC URTICARIA PATIENTS- RESULTS FROM THE FIRST INTERNATIONAL BURDEN OF ILLNESS STUDY (ASSURE-CSU)

Author(s)

Balp M1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, Weller K6, Maurer M6, Koenders J7, Knulst AC8, Halliday A9, Alexopoulos ST9, Nakonechna A10, Grattan C11, Abouzakouk M10, Sweeney C12, Radder C12, Wolin D13, McBride D14, Hollis K12, Tian H15, Elberink JN16
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 3Lynderm Research Inc., Toronto, ON, Canada, 4St Michael's Hospital, University of Toronto, Toronto, ON, Canada, 5Novartis Pharma GmbH, Nuernberg, Germany, 6Charite - Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharma B.V., Arnhem, The Netherlands, 8University Medical Center Utrecht, Utrecht, The Netherlands, 9Novartis Pharmaceuticals UK Limited, Surrey, UK, 10Hull and East Yorkshire NHS Hospital Trust, Hull, UK, 11Norfolk and Norwich University Hospital, Norwich, UK, 12RTI Health Solutions, Research Triangle Park, NC, USA, 13RTI Health Solutions, Ann Arbor, MI, USA, 14RTI Health Solutions, Manchester, UK, 15Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 16Unviersity Medical Center Groningen, Groningen, The Netherlands

Presentation Documents

OBJECTIVES: The ASSURE-CSU study is an observational, non-interventional, multinational study conducted to identify and quantify the humanistic and economic burden of illness in inadequately controlled CSU/CIU patients. Here we summarise the work and activity impairment among patients enrolled in Canada, Germany, UK, and the Netherlands. METHODS: This study included a 1-year retrospective medical record abstraction, a cross-sectional patient-reported outcomes survey and a 7-day prospective patient diary. Adult patients with CSU/CIU inadequately controlled with H1-antihistamines, with disease persisting for ≥12 months were assessed. Patients completed the Work Productivity and Activity Impairment-Specific Health Problem (WPAI-SHP) questionnaire, and results were described as mean (SD). Activity impairment was assessed among all patients; only employed patients were queried about work impairment.  RESULTS: A total of 86, 94, 74 and 93 patients completed the patient diary in Canada, Germany, UK and the Netherlands, respectively. Of these, 54.7%, 72.3%, 51.4% and 52.7% patients were currently employed, respectively. In the Canadian cohort, mean time loss due to absenteeism and presenteeism were 6.0% (12.0%) and 29.8% (26.3%) with an overall work productivity impairment of 30.6% (27.0%) and activity impairment of 38.3% (31.3%). Corresponding values for Germany were 7.4% (20.0%), 27.9% (25.7%), 30.5% (26.6%) and 36.4% (28.5%), respectively. In UK, mean time loss due to absenteeism was 9.9% (23.2%), presenteeism 33.1% (30.0%), overall work productivity impairment 35.3% (30.9%) and activity impairment 39.5% (30.3%). In the Netherlands, corresponding values were 2.3% (8.9%), 19.9% (25.4%), 20.7% (26.8%) and 31.0% (27.9%), respectively. The highest percentage of time missed due to CSU/CIU was reported in patients with moderate and severe CSU/CIU. CONCLUSIONS: The results are consistent among the countries and demonstrate that symptomatic patients with CSU/CIU experience a substantial impact on their daily activities and that many employed patients are affected at work by their disease.

Conference/Value in Health Info

2015-11, ISPOR Europe 2015, Milan, Italy

Value in Health, Vol. 18, No. 7 (November 2015)

Code

PSS68

Topic

Economic Evaluation

Topic Subcategory

Work & Home Productivity - Indirect Costs

Disease

Sensory System Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×